ULTRAGENYX PHARMACEUTICAL IN (RARE)
US90400D1081 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 351.4M 29.67% | 363.3M 3.39% | 434.249M 19.53% | 553.06M 27.36% | 655.96M 18.61% | 888.94M 35.52% | 1.38B 55.24% | 2.102B 52.32% | 2.903B 38.11% | 3.68B 26.77% | 3.527B -4.16% | |
| EBITDA YoY % growth | -368.46M -15.93% | -630.68M -71.17% | -543.202M 13.87% | -524.398M 3.46% | -427.47M 18.48% | -148.777M 65.20% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -381.7M -15.63% | -648.9M -70.00% | -569.208M 12.28% | -540.925M 4.97% | -463.832M 14.25% | -290.421M 37.39% | 80.035M 127.56% | 636.94M 695.83% | 1.157B 81.65% | 1.487B 28.52% | 1.724B 15.94% | |
| Operating Margin | -108.62% | -178.61% | -131.08% | -97.81% | -70.71% | -32.67% | 5.80% | 30.30% | 39.86% | 40.41% | 48.88% | |
| EPS YoY % growth | -6.71 -123.67% | -10.11 -50.67% | -8.33 17.61% | -6.28 24.59% | -5.19 17.40% | -3.12 39.82% | 0.42 113.34% | 5.81 1,294.00% | 10.86 87.11% | 15.75 44.96% | 14.65 -6.98% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.35 11.38% | -1.38 31.79% | -1.31 13.60% | -1.28 8.50% | -1.20 11.20% |
| Revenue Q2Q % growth | 149.37M 17.25% | 149.27M 37.16% | 160.02M 8.84% | 166.3M 19.22% | 177.28M 18.69% |
| EBITDA Q2Q % growth | -112.522M -17.16% | -94.179M 39.82% | -100.321M -1.69% | -84.896M 19.55% | -72.141M 35.89% |
| EBIT Q2Q % growth | -120.156M 1.55% | -125.181M 24.29% | -117.216M -0.73% | -114.308M 13.39% | -104.619M 12.93% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -1.40 37.22% | -1.48 | 0.08 | 5.37% |
| Q2 2024 Q2Q % growth | -1.52 32.44% | -1.73 | 0.21 | 12.01% |
| Q1 2024 Q2Q % growth | -2.03 12.88% | -1.77 | -0.26 | -14.94% |
| Q4 2023 Q2Q % growth | -1.52 29.63% | -1.65 | 0.13 | 7.99% |
| Q3 2023 Q2Q % growth | -2.23 36.29% | -2.12 | -0.11 | -5.20% |
| Q2 2023 Q2Q % growth | -2.25 0.44% | -2.12 | -0.13 | -6.35% |
| Q1 2023 Q2Q % growth | -2.33 -6.39% | -2.02 | -0.31 | -15.58% |
| Q4 2022 Q2Q % growth | -2.16 -20.67% | -2.18 | 0.02 | 1.14% |
| Q3 2022 Q2Q % growth | -3.50 -224.07% | -1.85 | -1.65 | -89.21% |
| Q2 2022 Q2Q % growth | -2.26 -24.86% | -1.79 | -0.47 | -26.47% |
| Q1 2022 Q2Q % growth | -2.19 -7.88% | -1.80 | -0.39 | -21.97% |
| Q4 2021 Q2Q % growth | -1.79 -383.78% | -1.37 | -0.42 | -30.74% |
| Q3 2021 Q2Q % growth | -1.08 4.42% | -1.44 | 0.36 | 24.80% |
| Q2 2021 Q2Q % growth | -1.81 -541.46% | -1.36 | -0.45 | -33.07% |
| Q1 2021 Q2Q % growth | -2.03 -6.28% | -1.26 | -0.77 | -60.89% |
| Q4 2020 Q2Q % growth | -0.37 77.16% | -1.18 | 0.81 | 68.76% |
| Q3 2020 Q2Q % growth | -1.13 42.35% | -1.28 | 0.15 | 11.98% |
| Q2 2020 Q2Q % growth | 0.41 121.69% | -1.57 | 1.98 | 126.03% |
| Q1 2020 Q2Q % growth | -1.91 -4.95% | -1.72 | -0.19 | -11.34% |
| Q4 2019 Q2Q % growth | -1.62 6.36% | -1.68 | 0.06 | 3.70% |
| Q3 2019 Q2Q % growth | -1.96 -12.64% | -1.71 | -0.25 | -14.62% |
| Q2 2019 Q2Q % growth | -1.89 -78.30% | -1.73 | -0.16 | -9.20% |
| Q1 2019 Q2Q % growth | -1.82 10.34% | -1.77 | -0.05 | -2.72% |
| Q4 2018 Q2Q % growth | -1.73 | -1.83 | 0.10 | 5.24% |
| Q3 2018 Q2Q % growth | -1.74 | -2.00 | 0.26 | 12.79% |
| Q2 2018 Q2Q % growth | -1.06 | -2.13 | 1.07 | 50.16% |
| Q1 2018 Q2Q % growth | -2.03 | -0.19 | -1.84 | -949.40% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 139.494M 42.27% | 138.51M | 984K | 0.71% |
| Q2 2024 Q2Q % growth | 147.026M 35.75% | 125.64M | 21.386M | 17.02% |
| Q1 2024 Q2Q % growth | 108.833M 8.30% | 118.33M | -9.497M | -8.03% |
| Q4 2023 Q2Q % growth | 127.392M 23.32% | 121.77M | 5.622M | 4.62% |
| Q3 2023 Q2Q % growth | 98.052M 8.11% | 111.82M | -13.768M | -12.31% |
| Q2 2023 Q2Q % growth | 108.309M 21.29% | 106.9M | 1.409M | 1.32% |
| Q1 2023 Q2Q % growth | 100.496M 25.78% | 106.78M | -6.284M | -5.88% |
| Q4 2022 Q2Q % growth | 103.3M 23.86% | 107.22M | -3.92M | -3.66% |
| Q3 2022 Q2Q % growth | 90.7M 11.15% | 98.121M | -7.421M | -7.56% |
| Q2 2022 Q2Q % growth | 89.3M 2.64% | 89.265M | 35K | 0.04% |
| Q1 2022 Q2Q % growth | 79.9M -19.62% | 85.327M | -5.427M | -6.36% |
| Q4 2021 Q2Q % growth | 83.4M -8.85% | 85.471M | -2.071M | -2.42% |
| Q3 2021 Q2Q % growth | 81.6M 0.12% | 83.178M | -1.578M | -1.90% |
| Q2 2021 Q2Q % growth | 87M 41.00% | 87.6M | -600K | -0.68% |
| Q1 2021 Q2Q % growth | 99.4M 173.83% | 78.58M | 20.82M | 26.50% |
| Q4 2020 Q2Q % growth | 91.5M 157.02% | 71.955M | 19.545M | 27.16% |
| Q3 2020 Q2Q % growth | 81.5M 215.89% | 56.107M | 25.393M | 45.26% |
| Q2 2020 Q2Q % growth | 61.7M 156.02% | 39.901M | 21.799M | 54.63% |
| Q1 2020 Q2Q % growth | 36.3M 99.45% | 37.477M | -1.177M | -3.14% |
| Q4 2019 Q2Q % growth | 35.6M 118.40% | 32.798M | 2.802M | 8.54% |
| Q3 2019 Q2Q % growth | 25.8M 118.64% | 29.699M | -3.899M | -13.13% |
| Q2 2019 Q2Q % growth | 24.1M 88.28% | 22.975M | 1.125M | 4.90% |
| Q1 2019 Q2Q % growth | 18.2M 70.09% | 18.663M | -463K | -2.48% |
| Q4 2018 Q2Q % growth | 16.3M | 13.925M | 2.375M | 17.06% |
| Q3 2018 Q2Q % growth | 11.8M | 11.58M | 220K | 1.90% |
| Q2 2018 Q2Q % growth | 12.8M | 5.532M | 7.268M | 131.38% |
| Q1 2018 Q2Q % growth | 10.7M | 53.916M | -43.216M | -80.15% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0.85% | 12.98% | 0.69% | 2.06% |
| Revenue | -0.07% | 3.79% | 0.05% | 1.07% |